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Abstract
Background: Poly(ADP-Ribose) polymerase (PARP) activity has been demonstrated fundamental in many cellular
processes, including DNA repair, cell proliferation and differentiation. In particular, PARP activity has been recently
found to affect proliferation, migration, and tube formation of human umbilical vein endothelial cells. In recent
times, PARP inhibitors have entered in clinical trials to potentiate cancer treatments by preventing DNA repair, but
little is known about the effects performed by different drug concentrations on neoangiogenesis, an essential step
in tumor growth.
Methods: Human umbilical vein endothelial cells were treated with 3 aminobenzamide (3ABA), a PARP inhibitor,
and tested for several different cellular parameters.
Results: Here we present in vitro evidence that a low concentration of 3ABA (50 μM), stimulates angiogenesis by
decreasing fibrinolytic activity, carried out by urokinase-type plasminogen activator (uPA), and by enhancing matrix
metalloprotease-2 (MMP-2) gelatinolytic activity, in fibroblast growth factor-2-stimulated endothelial cells. These
unbalanced pathways modify in vitro angiogenic steps, inhibiting chemoinvasion and stimulating tubulogenic
activity.
Conclusions: Our results suggest that the proangiogenic effect of low concentrations of 3ABA alerts on the
efficacy of PARP inhibitors to potentiate anticancer therapy. Moreover, they indicate that endothelial
chemoinvasion and tubulogenesis depend on distinct proteolytic pathways.
Background
Angiogenesis, the process of formation of new blood
vessels from preexisting capillaries, is essential for nor-
mal development in embryos. In adults, with some
exceptions like the female reproductive cycle and the
granular tissue in wound healing processes, angiogenesis
is an undesired process in certain pathological condi-
tions: in rheumatoid arthritis, in psoriasis, in diabetic
retinopathy, in the enlarging atherosclerosis plaque, and
in other pathologic phenomena including cancer [1]. In
particular, the growth of capillaries into tumors leads to
their enlargement and helps the tumor cells to metasta-
size. Angiogenesis requires endothelial cells to migrate,
proliferate, and ultimately assemble into tubes that regu-
late selective transport of blood cells and solutes from
their lumen to the interstitium and vice versa.
Endothelial cell survival and proliferation are a prere-
quisite for migration, sprouting and tubulogenesis.
Endothelial cell proliferation is stimulated by a number
of soluble factors and cytokines including fibroblast
growth factor (FGF). The basic form (FGF2) is known to
be a strong migration, sprouting, survival, and prolifera-
tion factor for endothelial cells, and plays a key role in
both normal blood vessel formation and in pathologic
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angiogenesis. Neovascularization, however, requires
endothelial cells to accomplish a number of other tasks
such as matrix degradation and migration to appropriate
sites.
It is well known that the serine protease urokinase-type
plasminogen activator (uPA) and the metalloproteases
(MMPs) regulate endothelial cell migration and adhesion
during angiogenesis. The uPA system is involved in
angiogenesis, cancer progression, invasion as well as
tumor prognosis [2]. This system is important for cell-
associated proteolytic activity that regulates cell migra-
tion and adhesion through binding of uPA to the uPA
receptor (uPAR) and subsequent extracellular matrix
degradation. MMPs participate not only in the remodel-
ing of basement membrane and extracellular matrix
(ECM), but also contribute to angiogenesis by releasing
ECM-bound growth factors, and by exposing cryptic,
proangiogenic integrin binding sites in the ECM [3].
Recently, we found that, in transformed endothelial
GM7373 cells, FGF2-dependent uPA upregulation is
affected by poly(ADP-ribose) polymerase (PARP) activity
stimulated by MAPK-dependent phosphorylation [4,5].
Poly(ADP-ribosyl)ation is a posttranslational modifica-
tion of proteins involved in most cellular functions. A
central role of PARP family enzymes (PARPs) was
demonstrated in many fundamental processes, including
cell proliferation and differentiation, by regulating gene
expression via posttranslational modification of gene
regulating proteins and histones [6]. Beneficial effects of
various PARP inhibitors have been demonstrated in
several forms of endothelial dysfunction [7,8]. Several
PARP inhibitors are currently undergoing clinical
evaluation [9,10], and a toxic effect against non prolifer-
ating cells was hypothesized [11]. Pharmacological inhi-
bitors of PARP affect proliferation, migration, and tube
formation of human umbilical vein endothelial cells
[12-14], but little is known about the molecular
mechanisms involved in these antiangiogenic effects.
Moreover, some compounds that inhibit tumor growth
at high concentrations can stimulate tumor growth at
lower concentrations, and an hormetic dose-response
curve is observed [15]. Several angiogenesis inhibitors
have been reported to produce a biphasic dose-efficacy:
statins [16], safrole oxide [17] and natural products
such as a-bisabolol [18]. To our knowledge, the effect
of low doses PARP inhibitors on angiogenesis in vitro
has not been previously explored.
In this study we were interested to elucidate whether
3ABA, one of the most utilised competitive inhibitor of
PARP, used at a low non toxic concentration (50 μM),
could affect migratory and tubulogenic capability of
endothelial cells, and if it could alter uPA/uPAR and
MMPs activities.
Methods
Cell cultures
Human umbilical vein endothelial cells (HUVEC) and
endothelial cell culture media were purchased from Clo-
netics (Cambrex, Walkersville, MD, USA). Cells were
grown on gelatin-coated plastic, in Endothelial cell
Growth Medium-2 (EGM-2,) supplemented with 10%
FCS (Euroclone, Milan, Italy), at 37°C in 5% CO2 humi-
dified atmosphere, and split at a 1:3 ratio for every pas-
sage. Cells from the 3rd to 8th passage were used. All
assays were performed on subconfluent cell monolayers.
Before the experiments the cells were incubated for 24
h in EGM-2 medium containing 2% FCS (starvation
medium). 3ABA (Sigma Chemical Co., St. Louis, MO,
USA) was added to the medium, at a final concentration
of 50 μM, 30 min before the supplementation of FGF2
(10 ng/ml; Boehringer, Mannheim, Germany). Cells
were detached with a solution of 0.05% trypsin and
0.02% EDTA in phosphate buffered saline (PBS).
Chemoinvasion assay
The Boyden chamber technique was performed to eval-
uate spontaneous (chemokinesis) and stimulated inva-
sion (chemoinvasion) through growth factor-reduced
Matrigel matrix (BD Bioscience, Bedford, MA, USA).
Polyvinylpyrrolidone-free polycarbonate filters (Neuro
Probe, Inc, Gaithersburg, MD, USA) with a pore size of
8 μm were coated with Matrigel (50 μg), allowed to
polymerize at 37°C for 60 min, and than placed over the
bottom chamber. Cells (2 × 105) from subconfluent cul-
tures were suspended in starvation medium (150 μl) and
loaded into the upper chamber. The effect of 3ABA was
analyzed by incubating the cells in the presence of
3ABA (50 μM) as previously indicated. For the che-
moinvasion test, a solution containing FGF2 (10 ng/ml)
as chemo-attractant was placed in the lower chamber.
At the end of the experimental time (8 h) the filters
were fixed in methanol. Non-migrated cells were
removed from the upper side of the filter with a cotton
swab, while migrated cells, adherent on the lower filter
surface, were stained with Diff-Quik (Mertz-Dade AG,
Dade International, Milan, Italy). The chemoinvasive
response was determined by counting the migrated cells
attached to the lower surface of the filter in 10 ran-
domly selected microscopic fields.
In vitro tubulogenic assay
The formation of vascular-like structures by endothelial
cells was assessed on growth factor-reduced Matrigel. In
brief, 500 μg of Matrigel were added to each well of 96-
well tissue culture plates and allowed to polymerize at
37°C for 60 min. To examine the effect of PARP inhibi-
tor 3ABA on in vitro tubulogenesis, HUVEC, cultured
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in starvation medium for 24 h, were supplemented for
30 min with 3ABA (50 μM) and Ilomastat (25 μM; Cal-
biochem, La Jolla, CA, USA) or anti-MMP-2 antibody
(10 μg/ml; Cell Signaling Technology, Beverly, MA,
USA), detached and seeded (1.5 × 104 cells/200 μl) on
Matrigel, in the presence of the above mentioned sub-
stances and of FGF2 (10 ng/ml). Cultures were moni-
tored for up to 24 h and photographed after 4 h with an
inverted microscope (Leitz DM-IRB) equipped with a
CCD camera. Three photographic fields from three
plates were scanned for each point. Results were quanti-
fied by measuring the percent field occupancy of tubules
using ImageJ 1.45b software (National Institutes of
Health, Bethesda, MD, USA).
Cell-associated plasminogen activator (PA) activity assay
To assay cell-associated PA activity cells were harvested,
washed twice with PBS and extracted on ice with 0.5%
Triton X-100 in 60 mM Tris-HCl pH 8.5 (T/T buffer).
Proteins (5 μg) were incubated in a microtiter plate
with 2 μg of purified human plasminogen (Boehringer,
Mannheim, Germany) and 25 μg of the plasmin chro-
mogenic substrate Chromozym PL (Tosyl-glycyl-prolyl-
lysine-4-nitranilide-acetate) (Boehringer, Mannheim,
Germany) in a final volume of 350 μl of T/T buffer.
After incubation at 37°C, the plate was read every
15 min at 405 nm wavelength with an automatic micro-
plate reader (Biorad, Hercules, CA, USA). Human uPA
(Serono, Roma, Italy) was used as standard.
Total cytoplasmic RNA extraction and semi-quantitative
RT-PCR
Total cytoplasmic RNA (RNATC) was extracted from
endothelial subconfluent culture according to the RNeasy
protocol (Qiagen GmbH, Hilden, Germany), and single
stranded cDNA was synthesized from 1 μg of RNATC. In
order to quantify the amount of uPA and uPAR gene
mRNA, a semi-quantitative polymerase chain reaction
(PCR) procedure was set up using the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a control house-
keeping gene. Sequences of the specific primers were: uPA
primers (5’-3’) forward AAAATGCTGTGTGCTGCT-
GACC and reverse CCCTGCCCTGAAGTCGTTAGTG;
uPAR primers (5’-3’) forward GCCCTGGGACAGGA
CCTCTG and reverse GCCGAGGCCCCATGAATCA
ATG; and human GAPDH primers (5’-3’) forward
CCACCCATGGCAAATTCCATGGCA and reverse TCT
AGACGGCAGGTCAGGTCCACC. The amplification
was performed for 35 cycles with an annealing tempera-
ture of 48°C for uPA and uPAR, of 55°C for GAPDH.
Intensity of bands corresponding to the expected size of
the amplified cDNA fragments of uPA, uPAR and
GAPDH, 704 bp, 612 bp and 598 bp respectively, were
quantified by densitometry using the Image J software.
Values were then expressed as the mean ± SEM of the
ratios between the normalized values of uPA or uPAR,
and GAPDH.
Gelatin zymography
MMP-2 and MMP-9 activity levels in the medium were
determined by gelatin zymography. Cell-free aliquots of
serum-free culture medium (conditioned medium) were
loaded on 8% SDS-PAGE gels containing 1 mg/ml gela-
tin. The loading volume of each sample was adjusted in
proportion to the protein content in the culture well
from which the sample was taken, and ranged from 8 to
25 μl. After electrophoresis, the gel was rinsed with 2.5%
Triton X-100 to remove SDS and restore enzyme activity,
incubated 16-20 h at 37°C in substrate buffer (20 mM
Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl2, 0.02%
dodecylpolyethyleneglycolether), stained with 0.1%
Comassie Brilliant Blue R-250 dye (Sigma Co.) in 40%
methanol/7% acetic acid for 1 h, and destained with 40%
methanol/7% acetic acid until bands were apparent: the
location of gelatinolytic activity was detected as clear
bands, and shown in Figure 5a as inverted dark bands for
a better visual prominence. HT1080 human fibrosarcoma
cell conditioned medium was used as a marker of mole-
cular weight. Arbitrary density of an individual cleavage
band was determined by scanning densitometry using
ImageJ software.
Statistical analysis
Data are expressed as mean ± SEM of the indicated num-
ber of experiments. Multiple comparisons were performed
by the Student-Newman-Keuls test, after demonstration of
significant differences among medians by non-parametric
variance analysis according to Kruskal-Wallis.
Results
Effect of 3ABA on FGF2 induced chemoinvasion and
in vitro tubulogenesis
HUVEC has been used to evaluate the effects of PARP
inhibitor 3ABA on migration and tubular-like networks
formation, which represent two important steps in the
angiogenic process.
In order to test the ability of a low dose of 3ABA (50 μM)
to modulate endothelial cell chemokinesis, and chemoinva-
sion in response to a migration stimulus, we used an
in vitro migration assay performed in Boyden chambers
(Figure 1). When FGF2 was used as a chemoattractant, it
induced a significative increase (+63%) of HUVEC ability to
invade Matrigel (* p < 0.05; n = 3) compared to unstimu-
lated cells. Treatment with 3ABA significantly inhibited
both FGF2-stimulated (# p < 0.05; n = 3) and spontaneous
(* p < 0.05; n = 3) cell invasiveness of about 55%.
In Figure 2 is reported the effect of 3ABA on in vitro
tubulogenesis. HUVEC were seeded in 96-well culture
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plates precoated with the growth factor-reduced Matri-
gel, and cellular morphology was photographed after 4 h
(Figure 2a). The quantification of tubulogenesis by mea-
suring the percent field occupancy of tubules, is reported
in Figure 2b. HUVEC cultured in the starvation medium
(Control) aggregate in cumuli of rounded cells producing
a few distorted cord-like structures. However, when
HUVEC were stimulated with FGF2 (10 ng/ml) they
started to differentiate in tube-like structures: cells
became elongated and formed thin cords of interconnect-
ing cells mimicking the neoangiogenesis process in vivo
(* p < 0.05; n = 6). Exposure to 3ABA of FGF2-stimulated
cells enhanced tube formation with a rise of the number
of interconnections, and the thickness of tubules (* p <
0.05, compared to control; # p < 0.05 compared to FGF2
stimulated cells; n = 6), while supplementation of 3ABA
alone did not affect cell morphology.
Effect of 3ABA on cell-associated plasminogen activator
(PA) activity
Cell-associated (PA) activity of HUVEC is reported in Fig-
ure 3. Cells were cultured in starvation medium (Control)
and supplemented with FGF2 (10 ng/ml), in the absence
and in the presence of 3ABA. Treatment of HUVEC with
FGF2 for 6 h and 24 h produced a significative increase in
cell-associated PA activity (+60 and 70% respectively; * p <
0.05 compared to control cells; n = 4). This increase was
prevented by 3ABA treatment, maintaining the PA activity
at basal levels (# p < 0.05 compared to FGF2 stimulated
cells; n = 4). Treatment with 3ABA alone did not modify
the basal level of cell-associate PA activity.
Effect of 3ABA on uPA and uPAR gene expression
Since cell associated PA activity induced by FGF2 in
endothelial cells is mostly dependent on urokinase type
plasminogen activity (uPA) rather than on other pro-
teases [19], we studied the effect of 3ABA on the level
of uPA mRNA. The increase of cell-associated PA activ-
ity in FGF2-stimulated cells was confirmed by the
increased expression of uPA mRNA. Figure 4 shows (a)
a typical densitometric pattern of uPA, uPAR and
GAPDH cDNAs, and (b) the quantification of uPA and
uPAR cDNAs amplified by PCR, with GAPDH as a con-
trol house-keeping gene. On the basis of the ratios
between normalized values of uPA amplified products
and of GAPDH products, we found that cells exposed to
FGF2 for 24 h showed a 75% increase of uPA-mRNA
(Figure 4b, left side; * p < 0.05 compared to control
cells; n = 3). The addition of 3ABA inhibited FGF2-sti-
mulated uPA gene expression (# p < 0.05 compared to
FGF2 stimulated cells; n = 3), while it did not affect
basal levels, confirming results previously obtained in
transformed endothelial cells GM7373 [4]. No variation
in uPAR mRNA levels was found in the presence of
FGF2 nor in the presence of 3ABA, at least after 24 h of
treatment (Figure 4b, right side).
Effect of 3ABA on gelatinolytic activity
Gelatin zymography analysis was utilised to investigate
whether MMP activities were modulated by 3ABA treat-
ment in FGF2 stimulated HUVEC. As shown in Figure
5a, HUVEC displayed both the 72 kDa (pro-MMP-2),
and the 64 kDa (intermediate MMP-2) and 59 kDa
(active MMP-2), forms of the enzyme. They did not
express MMP-9 activity. Exposure of FGF2-stimulated
cells to 3ABA induced an increase in the active form of
MMP-2 compared to both starved cell (Control) and
FGF2 cultured cells. No variation in gelatinolytic activity
was found in the presence of 3ABA alone, compared to
control. On the basis of image analysis of zymogram,
the percentage of MMP-2 active form (64 and 59 kDa
MMP-2) over the summation of pro-MMP-2 plus
MMP-2 amounts (Σ) was calculated. The activities of
the MMP-2 active forms, were reported in Figure 5c as
percent of the control. Statistical analysis, performed
only for the active form, showed a significative increase
of MMP-2 activity in FGF2 plus 3ABA treated cells
compared to FGF2 stimulated ones (# p < 0.05; n = 3)
and to control (* p < 0.05; n = 3).
Figure 1 Effect of 3ABA on in vitro chemoinvasion. Starved
HUVEC were plated in the upper Boyden chamber and treated
without and with 3ABA (50 μM) for 6 h. FGF2 was used in the lower
compartment as chemoattractant. FGF2 induced a significative
increase (+63%) of cells ability to invade Matrigel, compared to
unstimulated cells. Treatment with 3ABA significantly inhibited both
FGF2-stimulated and spontaneous cell invasiveness of about 55%.
Values are expressed as the number of cells migrated through
pores, and are mean ± SEM of three experiments. Multiple
comparisons were performed by the Student-Newman-Keuls test,
after Kruskal-Wallis analysis. (* p < 0.05 compared to control; # p <
0.05 compared to FGF2 stimulated cells).
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Figure 2 Effect of 3ABA on in vitro tubulogenesis. (a) Representative photographic fields showing the effect of 3ABA on in vitro tubulogenesis.
HUVEC tubulogenesis assay was performed in the absence (Control), in the presence of FGF2 (10 ng/ml), of FGF2 plus 3ABA (50 μM), and of 3ABA.
Pictures were taken after 4 h. HUVEC stimulated with FGF2 started to differentiate in tube-like structures. Exposure to 3ABA of FGF2-stimulated cells
enhanced tube formation with a rise of the number of interconnections, and the thickness of tubules. (b) Quantification of tubulogenesis after
3ABA treatment. Results were quantified by measuring the percent field occupancy of tubules. Values are mean ± SEM of six experiments. The
percent decrease/increase of tubulogenesis is referred to control untreated cells taken as 100%. Multiple comparisons were performed by the
Student-Newman-Keuls test, after Kruskal-Wallis analysis. (* p < 0.05 compared to control; # p < 0.05 compared to FGF2 treated cells).
Caldini et al. Vascular Cell 2011, 3:12
http://www.vascularcell.com/content/3/1/12
Page 5 of 10
Effect of MMP-2 activity inhibition on in vitro
tubulogenesis
In order to test whether MMP-2 contributes to the forma-
tion of new tubes in vitro, we used an unspecific MMPs
inhibitor (Ilomastat), and a specific MMP-2 inhibitor
(anti-MMP-2 antibody). Representative images of HUVEC
cultured on growth factors-reduced Matrigel for 4 h with
FGF2 in the presence of 3ABA, of 3ABA plus Ilomastat, of
3ABA plus anti-MMP-2 antibody are reported in Figure
6a. The quantification of the results by measuring the per-
cent field occupancy of tubules is reported in Figure 6b.
The length of the vascular network decreased significantly
in response to both Ilomastat and anti-MMP-2 antibody
(# p < 0.05 compared to FGF2 plus 3ABA stimulated cells;
n = 6) These data confirmed the importance of MMP-2
activity in 3ABA stimulated angiogenesis.
Discussion
The present study shows that treatment of FGF2-stimu-
lated HUVEC with a low dose of 3ABA (50 μM), a well
known inhibitor of PARP enzymes, affects angiogenesis
leading to inhibition of cell invasion on growth factors-
reduced Matrigel and stimulating cells morphogenesis in
an in vitro tube-forming assay. At the same time, 3ABA
stimulates MMP-2 activation, but negatively affects the
FGF2-mediated uPA upregulation, inhibiting both pro-
tease activity and mRNA amount.
Angiogenesis is a complex process that includes several
steps. It begins with the activation of endothelial cells by
growth factors, followed by enzymatic degradation of the
subendothelial capillary basement membrane by specific
proteases, such as uPA and MMPs, allowing endothelial
cells to detach from adhesive proteins. Then, cells migrate
into the stroma space, proliferate and differentiate into
patent structures, by aligning and forming vascular loops.
At last, capillary tubes develop with the formation of tight
junctions between the cells and the deposition of new
basement membrane. Angiogenesis has been generally stu-
died using a variety of approaches: both in vivo and in
vitro models were developed to further explore individual
steps and to better understand the molecular mechanisms
involved in the angiogenic process. Previous studies from
our laboratory have demonstrated that PARP inhibition
could affect gene expression of the serine protease uPA by
MAPK-dependent pathway, in transformed bovine
endothelial cells [4,5]. Given the critical role of uPA and
uPAR in angiogenesis and in many human diseases
[20,21], it would be of great interest to evaluate the effect
of PARP inhibition on some individual steps of angiogen-
esis which involve both uPA and uPAR gene expression
Figure 3 Effect of 3ABA on cell-associated plasminogen
activator (PA) activity. PA activity was determined
spectrophotometrically in untreated HUVEC (Control), and after
treatment for 6 and 24 h with FGF2 (10 ng/ml), with FGF2 plus
3ABA (50 μM), with 3ABA. Treatment of cells with FGF2 for 6 and 24
h produced a significative increase in cell-associated PA activity (+60
and 70% respectively) compared to control cells. Values are
expressed as International Unit (IU) enzyme/mg protein and are
mean ± SEM of four experiments. Multiple comparisons were
performed by the Student-Newman-Keuls test, after Kruskal-Wallis
analysis. (* p < 0.05 compared to control; # p < 0.05 compared to
FGF2 treated cells).
Figure 4 Effect of 3ABA on uPA and uPAR gene expression. (a)
Representative experiment of uPA and uPAR gene expression
analyzed in HUVEC untreated (Control) and treated with FGF2 (10
ng/ml), with FGF2 plus 3ABA (50 μM), and with 3ABA, for 24 h.
cDNAs were serially diluted and amplified by PCR using specific
primers for uPA, uPAR gene or GAPDH as a control housekeeping
gene. Cells exposed to FGF2 for 24 h showed an increase in uPA-
mRNA compared to control cells, while exposure to 3ABA inhibited
FGF2-stimulated uPA gene expression. No difference in uPAR-mRNA
was found. (b) Quantification of uPA and, uPAR gene expression.
Values are expressed as ratio between normalized integrated
densities of uPA, uPAR and GAPDH PCR products, and are mean ±
SEM of three experiments. Multiple comparisons were performed by
the Student-Newman-Keuls test, after Kruskal-Wallis analysis. (* p <
0.05 compared to control; # p < 0.05 compared to FGF2 treated
cells).
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and MMP-2 activity in a normal human cellular experi-
mental system.
The role of PARPs in angiogenesis has been recently
pointed out by several authors [12-14,22,23]. A number of
structurally distinct PARP inhibitors (3-aminobenzamide
1-5 mM, PJ34 10-100 μM, 5-aminoisoquinolinone-hydro-
chloride, and 1,5-isoquinolinediol) showed antiangiogenic
effects by inhibiting growth factor expression, or by inhi-
biting growth factor-induced cellular proliferative
responses [23,24], but the direct toxic effect of PARP inhi-
bitors on cellular metabolism must not be disregarded. In
fact, high doses (10 μM) of PARP inhibitor PJ34 proved to
be cytotoxic on melanoma cells [25]. This cytotoxic effect
was evidenced to be independent on DNA damage, but
dependent on other housekeeping roles. Moreover, since it
reversed when the drug was removed from the medium, it
would be of great interest to identify the real concentra-
tion of drugs in an in vivo system, as well as the pharma-
cological effects when the concentration of PARP
inhibitors fall down inside the microenvironment. In this
study we used 3ABA, an extensively studied first genera-
tion PARP inhibitor, at a low concentration (50 μM),
mainly because at this concentration the drug did not
affect viability and proliferative potential of endothelial
cells, as well as DNA integrity, but also in order to
Figure 6 Effect of MMP-2 inhibition on in vitro tubulogenesis.
(a) Representative photographic fields showing the effect of MMP-2
inhibition on in vitro tubulogenesis of HUVEC treated for 4 h with
FGF2 (10 ng/ml) in the presence of 3ABA (50 μM), of 3ABA plus
Ilomastat (25 μM), of 3ABA plus anti-MMP-2 antibody (10 μg/ml). (b)
Quantification of tubulogenesis. Results were quantified by
measuring the percent field occupancy of tubules. FGF2-stimulated
HUVEC treated with 3ABA decreased the tube formation and the
length of the vascular network when supplemented with MMP-2
inhibitor Ilomastat and anti-MMP-2 antibody. Values are mean ±
SEM of six experiments. The percent decrease/increase of
tubulogenesis is referred to FGF2 plus 3ABA treated cells taken as
100%. Multiple comparisons were performed by the Student-
Newman-Keuls test, after Kruskal-Wallis analysis. (# p < 0.05
compared to FGF2 plus 3ABA treated cells).
Figure 5 Effect of 3ABA on MMPs gelatinolytic activity. (a)
Representative zymogram, showing MMP-2 and MMP-9 activity in
medium from untreated cells (Control), in the presence of FGF2 (10
ng/ml), of FGF2 plus 3ABA (50 μM), and of 3ABA. HT1080 human
fibrosarcoma cell conditioned medium was used as a marker of
molecular weight. The areas of protease activity appeared as dark
bands. (b) On the basis of image analysis of zymogram reported in
Figure 5a, the percent amount of MMP-2 active form (MMP-2) over
the summation (Σ) of pro-MMP-2 plus MMP-2 amounts was
calculated. (c) Quantification of MMP-2 activity. Densitometric
analysis of MMP-2 activity in medium from cells incubated in the
absence (Control), in the presence of FGF2, of FGF2 plus 3ABA, and
of 3ABA alone. Exposure of FGF2-stimulated HUVEC to 3ABA
induced an increase in the active form of MMP-2 compared to both
untreated cells (Control), and FGF2 stimulated cells. Values are
expressed as percent of control and are mean ± SEM of three
experiments. Multiple comparisons were performed by the Student-
Newman-Keuls test, after Kruskal-Wallis analysis. (* p < 0.05
compared to control; # p < 0.05 compared to FGF2 treated cells).
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specifically inhibit poly(ADP-ribosyl)ation without affect-
ing mono ADP ribosylation [26], which has been recently
identified as a mechanism for regulating many different
aspects of cell physiology [27].
We investigated two important steps of angiogenesis:
migration and tubulogenesis in vitro, where protease
activities are particularly relevant. We found that 3ABA
at low doses (50 μM) affects these steps by two mechan-
isms: i) it dramatically inhibits chemoinvasion, ii) it
enhanced differentiation by inducing tube-like structures.
Many molecules inhibit separate steps of angiogenesis:
plasminogen activator inhibitors block endothelial cell
invasion, intracellular signaling inhibitors block endothe-
lial cell migration and proliferation, and matrix metallo-
protease inhibitors block tubulogenesis [28,29]. Matrigel
invasion assay revealed a marked reduction in both spon-
taneous and induced chemoinvasion of 3ABA-treated
cells compared to control cells. It is likely that such an
effect could be related not only to a direct 3ABA effect
on any FGF2-independent metabolism, but also to any
growth factor constitutively present at a low concentra-
tion within the growth factor reduced Matrigel.
It is well known that FGF2-induced endothelial cell
migration is uPA mediated. The plasminogen activator
system is an important participant in diverse physiological
processes including arterial remodelling and angiogenesis.
In particular, uPA plays a pivotal role in the regulation of
cell migration during tissue remodelling, through proteoly-
sis-dependent and proteolysis-independent mechanisms.
The coordinated expression of uPA and uPAR exists at
cell-substrate and cell-cell contact sites. The binding of
urokinase to uPAR provides both a strictly localized pro-
teolysis of extracellular matrix in the direction of cell
movement, and the initiation of a signal transduction cas-
cade, regulating cytoskeleton reorganization, adhesive con-
tact at the leading edge of the cell, and chemotaxis. In this
study, 3ABA treatment significantly decreased uPA
expression and activity in FGF2-treated cells, and
decreased cell movement in response to FGF2 as the che-
motactic factor. Collectively, these evidences suggested a
relationship between 3ABA treatment and down-regula-
tion of uPA gene expression in angiogenic processes, but
it cannot be excluded that it might be due to the impaired
ability of PARP to control the transcription of specific
genes other than uPA.
Since the migratory response elicited by FGF2 in bovine
aortic endothelial cells was secondary to the induction and
autocrine binding of uPA to the uPA receptor, we exam-
ined the possibility that uPAR mRNA could be affected
too; no difference in uPAR expression was shown in
3ABA cultured cells. Proteases such as uPA and MMPs
are key molecules involved in invasion, however the main
function of these proteases may not only be the remodel-
ling of the extracellular matrix, but also the processing of
a range of molecules involved in angiogenesis. For exam-
ple, proteases may modify growth factor action by cleaving
their receptors. In particular, it is well known that gelati-
nase MMP-2 is able to cause the shedding of FGF recep-
tor-1. Thus, we investigated the gelatinase activity in
3ABA treated HUVEC. Gelatin zymography of the med-
ium revealed that 3ABA treatment induced endothelial
cells to produce small but significant amounts of the
cleaved and active MMP-2 form. MMP-2 activation is
independent by serine proteases [30] whose activity
remained at basal level in FGF2 plus 3ABA-treated
HUVEC. High concentration of PARP inhibitors down
regulated MMP-2 activity in those experimental systems
where angiogenesis resulted inhibited [31], stressing the
role of PARP in cellular protease activity regulation.
Moreover, the ability to form a complete tubular network
can be strengthened by 3ABA supplementation to a culture
medium. Our results are consistent with the study of
Schnaper et al. [32], where the formation of tubular net-
works is increased by the addition of recombinant gelati-
nase A (MMP-2), and decreased when neutralizing
antibodies or the tissue inhibitor of metalloproteases
(TIMP) is added. The importance of MMP-2 in tubulogen-
esis induced by 3ABA was confirmed by MMP-2 neutrali-
zation with specific antibody, and with Ilomastat that
actually decreased tubulogenesis on Matrigel.
The inhibitory effect on tubulogenesis of high concen-
tration of PARP inhibitors, as reported in the literature
[12-14,22,23] seems to disagree with our results: this could
be explained by the competition between PARP inhibitors
and substrate for binding to MMP-2 [31] that could be
ineffective at low doses of inhibitors. A non specific effect
on other aspects of cell physiology could be also involved,
such as on the mono ADP ribosylation activity [26] that
results inhibited by high doses of 3ABA (> 1 mM).
The present study might open a promising perspective
in regard to future investigation of PARP inhibitor-
dependent modulation of angiogenesis. Further investi-
gations are necessary to clarify the role of PARP on the
regulation of gelatinase activation; in particular, it will
now be intriguing to understand whether PARP plays a
role on the two known pathways involved in the activa-
tion of the latent zymogen, namely Membrane Type
MMP (MT1-MMP) and Activated Protein C (APC).
Moreover, the recently proposed mechanism that links
downregulation of PARP and enhanced vascular
endothelial growth factor (VEGF) expression [24],
caught our attention as it was recently reported that
VEGF induced MMP-2 protein activation [33].
Conclusions
Our study focuses on the effect of PARP inhibitor 3ABA
on some important steps of angiogenesis, suggesting the
main role of the final concentration reached in the
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target microenvironment, since very low doses stimu-
lated cells to differentiate, and aggregate in tube-like
network, while, as reported in the literature, high doses
showed a clear anti angiogenic effect. Furthermore, our
results, using FGF2 as exogenous growth factor, suggest
that endothelial chemoinvasion and tubulogenesis are
dependent on distinct proteolytic pathways: invasion
seems to be dependent on uPA activity, while tubulo-
genesis on MMP-2 gelatinolytic activity.
The proangiogenic effect of low concentrations of the
PARP inhibitor 3ABA alerts on the efficacy of PARP
inhibitors to potentiate anticancer therapy, and suggests
that, in clinical trials, plasma drug concentrations need
to be accurately evaluated between administration
sessions.
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